Paroxetine
Paroxetine has been studied in 18 papers since 2016: 1 trial and 4 observational studies in people, 3 in animals, 10 reviews; 9 in the past year. It is an approved medicine. The newest paper, Oct 27, 2026: “Hormonal therapies are still first-line for menopausal vasomotor symptoms, but novel non-hormonal drugs are promising”.
2 new papers in 30 daysSee all 25 papers on paroxetine
At a glance
The findings reach people, from one lab or study; independent labs found the same change in worms or flies. 6 independent labs in 5 countries; 95 trials, 3 about aging, 60 with no results posted.
“At 12 weeks, the paroxetine group showed greater reduction in total MRS score compared with placebo (mean 16.9 ± 7.7 vs. 22.6 ± 6.1; mean difference -5.7, 95% CI -8.6 to -2.8; P < 0.001).”
1 of its findings points the other way.
- 6 independent labs in 5 countries
- 1 finding against
- 95 trials, 3 about aging, 60 with no results posted
- Funders: National Natural Science Foundation of China and others
- 1 of 14 findings with company ties
- Human trial1
- Humans4
- Animals1
- Model organisms2
Studies in people
1 study gave paroxetine to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases menopause Rating Scale scoremean difference -5.7, 95% CI -8.6 to -2.8, P < 0.001 up: Improves quality of lifemean difference 4.1, 95% CI 1.7 to 6.5, P = 0.001 | Randomized trial12 weeks | 90 peopleWomen<48 yearsMidlife adults; Patient cohorts | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, May 22, 2026 |
What did studies of paroxetine find?
13Studies of paroxetine measured 13 outcomes, among them lifespan, menopausal vasomotor symptoms and quality of life.
Lifespan
upin worms2downin worms1
2 studies
Lifespan
upin worms2downin worms1
Paroxetine shortens lifespan in worms.
“high doses consistently reduced lifespan”
Model organismshigh doses
Experimental gerontology
Paroxetine extends lifespan in worms (when exposure began early).
“low-dose paroxetine extended lifespan when exposure began early”
Model organismswhen exposure began earlylow-dose
Experimental gerontology
Paroxetine extends lifespan in worms.
“The results showed that paroxetine can prolong lifespan”
Model organisms
Paroxetine promotes longevity via ser-7-dop-4-IIS axis in Caenorhabditis elegans
GeroScience
Menopausal vasomotor symptoms
downin humans1
1 study
Menopausal vasomotor symptoms
downin humans1
Paroxetine decreases menopausal vasomotor symptoms in humans (MHT contraindicated or not preferred).
“non-hormonal drugs, such as paroxetine, fezolinetant and elinzanetant, offer effective alternative treatment options.”
ReviewMHT contraindicated or not preferred
Drugs & Therapy Perspectives
Quality of life
upin humans1
1 study
Quality of life
upin humans1
Paroxetine improves quality of life in humans (mean difference 4.1, 95% CI 1.7 to 6.5, P = 0.001).
“SF-36 scores also improved more with paroxetine (91.0 ± 6.4 vs. 86.9 ± 4.8; mean difference 4.1, 95% CI 1.7 to 6.5; P = 0.001).”
Human trial20 mg/day12 weeksfemalesn = 90
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Menopause Rating Scale score
downin humans1
1 study
Menopause Rating Scale score
downin humans1
Paroxetine decreases menopause Rating Scale score in humans (mean difference -5.7, 95% CI -8.6 to -2.8, P < 0.001).
“At 12 weeks, the paroxetine group showed greater reduction in total MRS score compared with placebo (mean 16.9 ± 7.7 vs. 22.6 ± 6.1; mean difference -5.7, 95% CI -8.6 to -2.8; P < 0.001).”
Human trial20 mg/day12 weeksfemalesn = 90
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Fat accumulation
no changein worms1
1 study
Fat accumulation
no changein worms1
Paroxetine showed no clear effect on fat accumulation in worms.
“without causing fat accumulation”
Model organisms
Experimental gerontology
Food intake
upin worms1
1 study
Food intake
upin worms1
Paroxetine increases food intake in worms.
“Paroxetine also increased food intake without causing fat accumulation”
Model organisms
Experimental gerontology
Lipofuscin accumulation
downin worms1
1 study
Lipofuscin accumulation
downin worms1
Paroxetine decreases lipofuscin accumulation in worms.
“paroxetine can prolong lifespan concomitant extension of healthspan as indicated by increasing mobility and reducing lipofuscin accumulation”
Model organisms
Paroxetine promotes longevity via ser-7-dop-4-IIS axis in Caenorhabditis elegans
GeroScience
Mobility
upin worms1
1 study
Mobility
upin worms1
Paroxetine improves mobility in worms.
“paroxetine can prolong lifespan concomitant extension of healthspan as indicated by increasing mobility and reducing lipofuscin accumulation”
Model organisms
Paroxetine promotes longevity via ser-7-dop-4-IIS axis in Caenorhabditis elegans
GeroScience
Spatial working memory
no changein mice1
1 study
Spatial working memory
no changein mice1
Paroxetine showed no clear effect on spatial working memory in mice (APPswe/PS1dE9 transgenic mice).
“it appears to have no effect on total number of granular neurons or spatial working memory.”
AnimalsAPPswe/PS1dE9 transgenic mice9 months
Neurobiology of disease
Amyloid plaque load
downin mice1
1 study
Amyloid plaque load
downin mice1
Paroxetine decreases amyloid plaque load in mice (APPswe/PS1dE9 transgenic mice).
“Paroxetine treatment from 9 to 18months of age reduced hippocampal amyloidosis without affecting the number of neuroblasts or granular neurons.”
AnimalsAPPswe/PS1dE9 transgenic micehippocampus9 months
Neurobiology of disease
All 13Fewer
What is paroxetine linked with?
1Studies link paroxetine with breast cancer.
Breast cancer
downin humans1OR 0.62
1 study
Breast cancer
downin humans1OR 0.62
Paroxetine lowers the risk of breast cancer in humans (current users) (OR 0.62, 95% CI 0.43-0.88).
“Paroxetine appeared protective, with a lower risk among current users (OR = 0.62; 95% CI: 0.43-0.88)”
Reviewcurrent usersfemales
Research SquarePreprint
Has paroxetine been tested in people?
3 of 95 about agingYes: 1 trial and 4 observational studies in people have been published, and 95 trials are registered.
About aging
Phase 2Completed
Phase 3Completed
Phase 3Completed
Approved
Dec 29, 1992Depressive Disorder, Major, Generalized Anxiety Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Social Anxiety Disorder
Jun 25, 1997Discontinued
Oct 9, 1998Discontinued
Feb 16, 1999Depressive Disorder, Major, Panic Disorder, Premenstrual Dysphoric Disorder, Social Anxiety Disorder
Jul 3, 2003Discontinued
Jun 28, 2013menopause, vasomotor symptoms, moderate to severe vasomotor symptoms associated with menopause
Repurposing
Phase 4Completed1 trial
Phase 3Terminated2 trials
Phase 4Results posted19 trials
Phase 4Status unknown1 trial
Phase 4Completed1 trial
Phase 4Completed1 trial
All 40Fewer
Readouts due
- Feb 28, 2027
A Phase I Study of NS-079 in Healthy Participants
Phase 1Recruiting
- Mar 2027
Antidepressant Therapy for Improved Blood Vessel Health After Preeclampsia
Early phase 1Recruiting
Stopped
NCT00926835TerminatedMajor depressive disorder
due to patient recruitment difficulties
Who is developing paroxetine?
3 companies: GlaxoSmithKline, Asceneuron and Teva Pharmaceuticals USA.
Trial sponsors
Company19 trialsPhase 43,290 people
HolsboerMaschmeyer NeuroChemie
Company1 trialPhase 480 people
Company4 trialsPhase 31,310 people
Company3 trialsPhase 31,970 people
Company3 trialsPhase 3130 people
Company2 trialsPhase 3665 people
Company1 trialPhase 3825 people
Company1 trialPhase 3614 people